BPC-157 Dosage: What the Research Literature Actually Reports

BPC-157 has no approved human dose, and no published human dose-ranging trial to derive one from. Every chart circulating online is an extrapolation from animal research, and most of them skip the step that makes such an extrapolation meaningful.

This covers what the literature actually reports, why converting it is not arithmetic anyone should trust blindly, and how to handle the vial math if you are working with the compound in a research setting.

What BPC-157 is

BPC-157 is a synthetic pentadecapeptide — fifteen amino acids — derived from a partial sequence of a protein found in human gastric juice. The preclinical literature, largely from a single research group over three decades, reports effects on tendon, muscle and gut healing in rodents.

The body of evidence is almost entirely animal work. That is the single most important fact about it, and it constrains everything that follows.

What the animal studies used

Published rodent studies typically report doses in micrograms or nanograms per kilogram of body weight, delivered intraperitoneally, intragastrically, or topically. The commonly cited range is roughly 10 µg/kg, with some protocols an order of magnitude either side.

The problem is what happens next. Multiplying 10 µg/kg by an 80 kg human gives 800 µg, and that number appears in charts everywhere — but a straight body-weight multiplication is not how interspecies dose conversion works.

Why the conversion is not straightforward

Standard practice converts between species using body surface area rather than mass, because metabolic rate does not scale linearly with weight. Applying the conventional rat-to-human factor reduces a per-kilogram figure by roughly six-fold, which produces a very different answer from a naive multiplication.

• Route differs. Rodent studies frequently use intraperitoneal or intragastric delivery, not subcutaneous injection.

• Species differ. Clearance, distribution, and receptor biology are not transferable by arithmetic.

• Endpoint differs. An induced tendon injury in a rat is not a proxy for any human condition.

• No safety data. Animal work establishes an effect, not a human therapeutic window.

The vial math

Whatever figure a protocol specifies, converting it to a syringe reading is straightforward arithmetic. The powder mass in the vial is fixed; the bacteriostatic water only sets concentration.

Reconstitution chart

Note the pattern: for small target amounts, adding more water produces larger unit readings that are easier to measure accurately. A 5-unit draw leaves little room for error; 15 units is far more forgiving. The peptide calculator handles any combination, and the BPC-157 research profile collects handling notes for the compound.

Storage

• Lyophilised: the stable form — cold, dark, sealed.

• Reconstituted: 2–8 °C, protected from light, never frozen.

• Window: the shorter of peptide stability in solution and the 28-day bacteriostatic water limit.

Injection versus oral

BPC-157 is sold both as a lyophilised powder for injection and as oral capsules, and the two are routinely discussed as if a single dose figure covered both. It does not.

The compound is described as stable in gastric juice, which is the basis for the oral products — but stability is not the same as absorption. A figure derived from studies using intraperitoneal or intragastric delivery in rodents cannot be carried across to an oral capsule in a human without knowing the bioavailability, and that figure is not established.

What is not known

The honest summary of BPC-157 is a compound with an interesting and consistent preclinical literature, and essentially no human evidence base. Specifically absent:

• Human dose-ranging. No published trial establishes an effective or a maximum tolerated dose.

• Long-term safety. Rodent studies run weeks. Nothing addresses sustained human exposure.

• Pharmacokinetics in humans. Half-life, distribution, and clearance are not characterised.

• Independent replication. A large share of the literature originates from one research group. That is not evidence of error, but independent replication is how a finding becomes robust, and it is thin here.

Reading vendor claims critically

Because there is no approved dose, vendor and blog dosing charts are the primary source most people encounter — and they are the least reliable one. Two patterns are worth recognising.

1. Precision without provenance. A chart specifying "250–500 mcg twice daily" reads as authoritative but usually cites nothing. Ask what study produced it and for which species and route.

2. The straight multiplication. A per-kilogram animal figure multiplied by human bodyweight, with no surface-area correction. This is the single most common error, and it inflates the result several-fold.

What can be verified is the material itself. The guide to reading a certificate of analysis covers what a COA does and does not establish, and the vendor comparison tracks pricing per milligram across suppliers.

Frequently asked questions

Is there a standard BPC-157 dose?

No. There is no approved dose and no human dose-ranging trial. Any chart presenting one is presenting an assumption.

Are oral capsules equivalent to injection?

They are not equivalent, and the two cannot share a dose figure. Oral and injected routes differ in bioavailability, so a number derived from injection studies does not transfer to a capsule.

What about BPC-157 with TB-500?

They are frequently discussed together and sold as blends. See the BPC-157 and TB-500 guide for how blended vials change the arithmetic, which is where most errors happen.